Photo by Institut Douglas / CC BY-NC-ND 2.0

The Finnish pharmaceutical company Herantis Pharma Plc has received funding from the Horizon 2020 program for its phase 1-2 clinical study aimed at adopting an innovative treatment for Parkinson’s disease. The EU grant will enable the extension of the clinical study’s CDNF treatment period to 12 months under two separate clinical protocols.

The TreatER project is to be implemented by a consortium of 11 members including Herantis as the formal sponsor of the clinical study, the owner of Cerebral Dopamine Neurotrophic Factor (CDNF) patents, and the University of Helsinki, Finland.

The consortium also includes three university hospitals responsible for patient treatments: Karolinska University Hospital and Lund University Hospital in Sweden, and Helsinki University Hospital in Finland.

More information: